Home   Chapter Home   Jobs   Conferences   Fellowships   Books


Lymphoma - B cell neoplasms

Non-Hodgkin Lymphoma


Reviewer: Nikhil Sangle, M.D., University of Utah and ARUP Laboratories (see Reviewers page)
Revised: 17 February 2011, last major update February 2011
Copyright: (c) 2001-2011, PathologyOutlines.com, Inc.

List of translocations

Relatively common translocations are listed below
See each topic for more complete lists:

● t(1;14)(p22;q32): bcl-10 and IgH; MALT lymphoma (% unknown)
● t(1;14)(p32;q11): SCL (tal-1) and T cell receptor delta/alpha; preT ALL (15-30%)
● t(1;14)(q21;q32); bcl9 and IgH; preB ALL (acute lymphoblastic leukemia/lymphoma), mantle cell lymphoma
● t(1;19)(q23;p13): PBX1 and E2A; preB ALL (30%)
● t(2;5)(p23;q35): ALK and NPM; anaplastic large cell lymphoma, T/NK subtypes (40-70%)
● t(2;8)(p12;q24): Ig Kappa and c-myc; Burkitt lymphoma (15%)
● t(2;18)(p12;q21): Ig Kappa and bcl2; follicular lymphoma (<5%)
● Trisomy 3: MALT lymphoma (% unknown)
● t(3;14)(q27;q32): bcl6 and IgH; diffuse large B cell lymphoma (30%), follicular lymphoma (10%)
● t(4;11)(q21;q23): AF4 and MLL; preB ALL (10%)
● t(4;14)(p16.3;q32): FGFR3/mmset and IgH; multiple myeloma (25-30%)
● t(5;14): IL3 gene and IgH; preB ALL and peripheral eosinophilia
● t(6;14)(p25;q32): mum/irf4 and IgH; multiple myeloma
● 7q isochromosome: hepatosplenic gamma/delta lymphoma (% unknown)
● Trisomy 8: hepatosplenic gamma/delta lymphoma (% unknown)
● t(8;13)(p11;q11-12): FGFR1 and ZNF 198; T cell lymphoblastic with eosinophilia (% unknown)
● t(8;14)(q24;q32): c-myc and IgH; Burkitt lymphoma (75%), ALL-type L3 (6%)
● t(8;21): ETO gene and AML1 gene; AML-M2
● t(8;22)(q24;q11): c-myc and Ig Lambda; Burkitt lymphoma (10%)
● 9p amplification: REL; primary mediastinal large B cell lymphoma (% unknown)
● t(9;14)(p13;q32): PAX5 and IgH; lymphoplasmacytic lymphoma (% unknown)
● t(9;22)(q34;q11): c-abl and bcr (Philadelphia chromosome); preB ALL (5% of children, 25% of adults), chronic myelogenous leukemia (about 95%, controversial)
● t(10;14)(q24;q11): HOX11 and T cell receptor delta/alpha; preT ALL (7%)
● deletion of 11q23: CLL (10-20%)
● t(11;14)(q13;q32): bcl1/PRAD1 and IgH; mantle cell lymphoma (90%), B cell prolymphocytic leukemia (20%), myeloma (3%)
● t(11;14): rhombotin 1/2 genes and IgH; T-ALL
● t(11;18)(q21;q21): API2 and MLT; MALT lymphoma (50%)
● Trisomy 12: B-CLL (30%)
● t(12;21)(p13;q22): ETV6-CBFA2 (TEL and AML1); preB ALL (20%)
● deletion 13q14: B -CLL (25-50%)
● Inversion 14(q11;q32) or other #14 translocations: T cell prolymphocytic leukemia (75%)
● t(14;15)(q32;q11-13); IgH and bcl8; diffuse large B cell lymphoma (3%)
● t(14;16)(q32;q23); IgH and c-maf; multiple myeloma
● t(14;18)(q32;q21): IgH and bcl2; follicular lymphoma (90%), diffuse large B cell lymphoma (30%)
● t(14;19)(q32;q13): IgH and bcl3; B-CLL
● t(15;17): retinoic acid receptor and PML gene; acute prolymphocytic leukemia, M3 (most)
● t(16;22);(q23;q11): cmaf and Ig lambda; multiple myeloma
● Trisomy 18: common in marginal zone lymphoma, MALT type

End of Lymphoma - B cell neoplasms > Non-Hodgkin Lymphoma > Cytogenetics

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).